Joseph Ec Marinas1, Whan B Kim1, Ali Shahbaz2, Judy K Qiang3, Simon Greaves4, Jensen Yeung5,6,7. 1. Department of Health Sciences, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. 2. Department of Medicine, School of Medicine, University of Ottawa, Ottawa, Ontario, Canada. 3. Department of Medicine, School of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 5. Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 6. Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 7. Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
Abstract
BACKGROUND/ OBJECTIVES: Data on biologic drug survival in real-world psoriasis treatment are limited. There is a need to evaluate long-term trends of biologic use outside the realm of clinical trials. METHODS: A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan-Meier plot analysis was used to determine 5-year drug survival rates. A log-rank test was used to compare the rates of drug survival between the studied biologics. RESULTS: For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5-year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics. CONCLUSION: A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.
BACKGROUND/ OBJECTIVES: Data on biologic drug survival in real-world psoriasis treatment are limited. There is a need to evaluate long-term trends of biologic use outside the realm of clinical trials. METHODS: A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan-Meier plot analysis was used to determine 5-year drug survival rates. A log-rank test was used to compare the rates of drug survival between the studied biologics. RESULTS: For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5-year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics. CONCLUSION: A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.
Authors: Laida Elberdín; Rosa M Fernández-Torres; Sabela Paradela; María Mateos; Eva Blanco; Vanesa Balboa-Barreiro; María I Gómez-Besteiro; Maria Outeda; Isabel Martín-Herranz; Eduardo Fonseca Journal: Dermatol Ther (Heidelb) Date: 2022-02-28